Weller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., … Sampson, J. H. (2017). Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply. Lancet Oncol, 18(12), e709–e710. https://doi.org/10.1016/S1470-2045(17)30856-2

Weller, Michael, Nicholas Butowski, David D. Tran, Lawrence D. Recht, Michael Lim, Hal Hirte, Lynn Ashby, et al. “Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply.” Lancet Oncol 18, no. 12 (December 2017): e709–10. https://doi.org/10.1016/S1470-2045(17)30856-2.

Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, et al. Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply. Lancet Oncol. 2017 Dec;18(12):e709–10.

Weller, Michael, et al. “Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply.” Lancet Oncol, vol. 18, no. 12, Dec. 2017, pp. e709–10. Pubmed, doi:10.1016/S1470-2045(17)30856-2.

Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O’Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH. Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply. Lancet Oncol. 2017 Dec;18(12):e709–e710.